The Life Sciences team advised SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) on its underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in the offering. SpringWorks raised aggregate gross proceeds of approximately $316.25 million before deducting underwriting discounts and commissions and estimated offering expenses.
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.
The Goodwin team was led by Sarah Ashfaq, Kingsley Taft, Alexandra Singer, Claire Treesh and Kevin Boyle, and included Julie Tibbets, Elizabeth Mulkey, Daniel Karelitz, Leon Peschel, Matt Wetzel and Maggie Wong.
For additional details about the offering, which was completed on Friday, December 8, 2023, please read the press release.